NI200700235A - Procesos y métodos para la preparación de cis-2- hidroximetil-4-citosin-1'-yl)-1,3- oxatiolane ópticamente activo o sales farmacéuticamente aceptables de los mismos - Google Patents

Procesos y métodos para la preparación de cis-2- hidroximetil-4-citosin-1'-yl)-1,3- oxatiolane ópticamente activo o sales farmacéuticamente aceptables de los mismos

Info

Publication number
NI200700235A
NI200700235A NI200700235A NI200700235A NI200700235A NI 200700235 A NI200700235 A NI 200700235A NI 200700235 A NI200700235 A NI 200700235A NI 200700235 A NI200700235 A NI 200700235A NI 200700235 A NI200700235 A NI 200700235A
Authority
NI
Nicaragua
Prior art keywords
optically active
cis
oxatiolane
citosin
hydroximethyl
Prior art date
Application number
NI200700235A
Other languages
English (en)
Inventor
Simion Dan
Cimpoia Alex
Original Assignee
Shire Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Canada Inc filed Critical Shire Canada Inc
Publication of NI200700235A publication Critical patent/NI200700235A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

Se proporciona un método para la resolución de un compuesto de fórmula (III), en configuración cis: También se proporciona un proceso para producir el compuesto ópticamente activo de fórmula (I) o (II): en donde R1, R2, R3 son como se define en la presente, el método y proceso involucran la producción, recuperación y conversión de sales diastereoméricas.
NI200700235A 2005-03-14 2007-09-11 Procesos y métodos para la preparación de cis-2- hidroximetil-4-citosin-1'-yl)-1,3- oxatiolane ópticamente activo o sales farmacéuticamente aceptables de los mismos NI200700235A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2005/000384 WO2006096954A1 (en) 2005-03-14 2005-03-14 Process and methods for the preparation of optically active cis-2-hydroxymethyl-4-(cytosin-1´-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof

Publications (1)

Publication Number Publication Date
NI200700235A true NI200700235A (es) 2012-05-23

Family

ID=36991222

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200700235A NI200700235A (es) 2005-03-14 2007-09-11 Procesos y métodos para la preparación de cis-2- hidroximetil-4-citosin-1'-yl)-1,3- oxatiolane ópticamente activo o sales farmacéuticamente aceptables de los mismos

Country Status (15)

Country Link
EP (1) EP1866303B1 (es)
JP (1) JP5001254B2 (es)
KR (1) KR100993031B1 (es)
CN (1) CN101142211B (es)
AP (1) AP2261A (es)
AU (1) AU2005329355B8 (es)
BR (1) BRPI0520041A2 (es)
CA (1) CA2599825C (es)
ES (1) ES2446102T3 (es)
IL (1) IL185370A0 (es)
MX (1) MX2007011274A (es)
NI (1) NI200700235A (es)
NO (1) NO338553B1 (es)
NZ (1) NZ560972A (es)
WO (1) WO2006096954A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110257396A1 (en) * 2006-10-30 2011-10-20 Lupin Limited Process for the manufacture of cis(-)-lamivudine
IN2015DN02599A (es) 2007-09-28 2015-09-18 Avexa Ltd
EP2358708B1 (en) * 2008-12-08 2013-06-12 Hetero Research Foundation Optical resolution of substituted 1.3-oxathiolane nucleosides
WO2011141805A2 (en) 2010-05-14 2011-11-17 Lupin Limited An improved process for the manufacture of lamivudine
JP2012136526A (ja) * 2012-02-09 2012-07-19 Shire Canada Inc 光学的に活性なcis−2−ヒドロキシメチル−4−(シトシン−1’−イル)−1,3−オキサチオランまたはその薬学的に許容される塩の製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2095613C (en) * 1990-11-13 2001-01-02 Bernard Belleau Substituted 1, 3-oxathiolanes and substituted 1, 3-dithiolanes with antiviral properties
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US6228860B1 (en) 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
NZ241625A (en) * 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
US6600044B2 (en) * 2001-06-18 2003-07-29 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers

Also Published As

Publication number Publication date
AU2005329355B2 (en) 2011-08-18
CN101142211B (zh) 2013-06-05
AP2261A (en) 2011-07-26
AU2005329355A1 (en) 2006-09-21
NO20075224L (no) 2007-10-11
NZ560972A (en) 2009-07-31
KR20080008322A (ko) 2008-01-23
MX2007011274A (es) 2008-03-13
WO2006096954A1 (en) 2006-09-21
EP1866303A1 (en) 2007-12-19
ES2446102T3 (es) 2014-03-06
EP1866303B1 (en) 2013-11-27
KR100993031B1 (ko) 2010-11-08
CA2599825A1 (en) 2006-09-21
AP2007004147A0 (en) 2007-10-31
IL185370A0 (en) 2008-02-09
CA2599825C (en) 2012-06-19
EP1866303A4 (en) 2010-05-19
AU2005329355B8 (en) 2012-02-23
NO338553B1 (no) 2016-09-05
JP2008533056A (ja) 2008-08-21
JP5001254B2 (ja) 2012-08-15
CN101142211A (zh) 2008-03-12
BRPI0520041A2 (pt) 2009-04-14

Similar Documents

Publication Publication Date Title
NZ599342A (en) Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
AR054735A1 (es) Proceso de obtencion de un derivado de piperazina
EA200800886A1 (ru) Способ получения 1-н-имидазо[4,5-с]пиридинов и их аналогов
MA35451B1 (fr) Dérivés de pyrrolopyrimidine et de purine
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
NI200700235A (es) Procesos y métodos para la preparación de cis-2- hidroximetil-4-citosin-1'-yl)-1,3- oxatiolane ópticamente activo o sales farmacéuticamente aceptables de los mismos
IN2014MN02582A (es)
MX2009010890A (es) Nuevo proceso para la fabricacion del compuesto de 2-hidroxi-3-[5-(morfolin-4-ilmetil)piridin-2-il]1h-indol-5-carbon itrilo 701.
MX2009011365A (es) Compuestos anulares de seis miembros en puente.
EA200601845A1 (ru) НОВЫЕ β-АГОНИСТЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ
WO2009066735A1 (ja) 2-アザアダマンタン類の製造方法
EA200600485A1 (ru) Способ получения производных 2-оксо-1-пирролидина
EA201071120A1 (ru) Способ получения гетероарилбензопроизводных сульфаматов и кристаллической формы n-((2s)-6-хлор-2,3-дигидро-l,4-бензодиоксин-2-ил)метилсульфамида
AR024494A1 (es) Proceso para la preparacion de derivados de ciclopentano sustituido y novedosas estructuras cristalinas de los mismos
UY29498A1 (es) Derivados de aminoácidos
UY27959A1 (es) Nuevos agonistas ppar alfa y ppar gama
ATE466003T1 (de) Herstellung von 2-aminothiazol-5- carbonsäurederivaten
NI201000065A (es) CARBONO UNIDO A LOS MODULADORES DE LA y-SECRETASA.
DE602005013007D1 (de) Verfahren zur herstellung von lactonen
ATE538102T1 (de) Verfahren zur herstellung eines chinazolinderivats
MY146568A (en) Process and methods for the preparation of optically active cis-2-hydroxymethyl-4-(cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof
DE502007002745D1 (de) Verfahren zum herstellen von lysobactin-derivaten
UY27560A1 (es) Compuestos hexaciclicos-
ATE365739T1 (de) Verfahren zur herstellung optisch aktiver 3- chinuclidinole
ATE415388T1 (de) Verfahren zur herstellung von enantiomerenreinen 4-pyrrolidinophenyl- benzyletherderivaten